泌尿系统肿瘤生物化学、分子生物学☕️、蛋白质组学和尿路修复重建等

研究（尤其前列腺癌雄激素代谢和诊疗💍、尿道狭窄和复杂性尿瘘修复)

Biochemistry, molecular biology, proteomics and urinary tract repair and reconstruction of urinary system tumors Research (especially androgen metabolism and management in prostate cancer, urethral stricture and complex fistula repair)

中国医师协会泌尿外科分会委员🙆🏿、中国医师协会男科与性医学医师分会委员🌎、中国抗癌协会泌尿生殖肿瘤专委会常委🚯、上海市医学会泌尿外科专科分会副主任委员、上海医师协会男科分会副会长、上海市抗癌协会泌尿肿瘤专业委员会副主任委员👴🏿、中国康复医学会产后康复专业委员会泌尿康复学组副主任委员、上海介入医疗器械工程技术研究中心泌尿男科医学工程专业委员会副主任委员、中国激光学会上海分会泌尿外科学专业委员会副主任委员、中西医结合学会上海泌尿男科学分会副主任委员.

Member of the Urology Branch of the Chinese Medical Doctor Association, member of the Andrology and Sexual Medicine Branch of the Chinese Medical Doctor Association, member of the Standing Committee of the Urogenital Tumor Special Committee of the Chinese Anti-Cancer Association, deputy chairman of the Urology Branch of the Shanghai Medical Association, vice chairman of the Andrology branch of the Shanghai Medical Doctor Association, deputy chairman of the Urologic tumor Professional Committee of the Shanghai Anti-cancer Association, and the postpartum rehabilitation department of the Chinese Rehabilitation Medical Association Vice Chairman of the Urology Rehabilitation Group of Industry Committee, vice chairman of the Urology Andrology Medical Engineering Committee of Shanghai Interventional Medical Device Engineering and Technology Research Center, vice chairman of the Urology surgery committee of the Chinese Laser Society Shanghai Branch, and vice chairman of the Shanghai Urology Branch of Integrated Chinese and Western Medicine Society.

承担课题：

undertake a project:

（1）国家自然科学基金委员会, 面上项目, 82472857, 雄烷二酮代谢通路介导前列腺癌异质性的机制及其病理意义, 2025.01-2028.12, 49万元, 主持，在研

(1) National Natural Science Foundation of China, Surface Project, 82472857, Androstanedione metabolic pathway mediates the heterogeneity of prostate cancer and its pathological significance, 2025.01-2028.12, 490,000 yuan, host, in research

（2）上海市同济医院泌尿外科主任医师吴登龙入选2022年东方英才计划领军项目，120万，主持，在研

(2) Wu Denglong, chief physician of urology department of Shanghai Tongji Hospital, was selected as the leading project of the 2022 Oriental Talents Plan, with 1.2 million yuan, hosted and in research

(3) 上海市科学技术委员会, 面上, 22ZR1456800, BRD4调控CYP19A1并抑制AR表达在延缓去势抵抗性前列腺癌进展中的机制研究, 2022-04 至 2025-03, 20万元, 在研, 主持

(3)Shanghai Science and Technology Commission, Surface, 22ZR1456800, BRD4 regulation of CYP19A1 and inhibition of AR expression in delaying the progression of castration-resistant prostate cancer mechanism research, 2022-04 to 2025-03, 200,000 yuan, in progress, Host

(4) 上海申康医院发展中心, 市级医院新兴前沿技术联合攻关项目, SHDC12019112 , 阿比特龙联合度他雄胺治疗去势抵抗性 前列腺癌的多中心、随机、对照临床研究, 2019-11 至 2022-11, 100万元, 结题, 主持

(4) Shanghai Shenkang Hospital Development Center, Joint Research Project on Emerging Frontier Technologies in Municipal Hospitals, SHDC12019112, multi-center, randomized, controlled clinical study of Aberaterone combined with Dutasteride in the treatment of castration-resistant prostate Cancer, 2019-11 to 2022-11, 1 million yuan, conclusion, Host

(5) 上海申康医院发展中心, 重大临床研究项目, SHDC2020CR3074B, 光声多模态成像技术用于前列腺癌诊断的前瞻性临床研究, 2020-10 至 2022-09, 100万元, 结题, 主持

(5) Shanghai Shenkang Hospital Development Center, Major Clinical Research Project, SHDC2020CR3074B, Photoacoustic Multimodal Imaging for the diagnosis of prostate cancer Prospective clinical research, 2020-10 to 2022-09, 1 million yuan, Conclusion, Host

(6) 科学技术部, 数字诊疗装备研发重点专项, 2017YFC0111404, 多模态系统的前列腺癌诊断临床验证, 2017-07 至 2021-12, 69万元, 结题, 主持

(6) Ministry of Science and Technology, Key Project of Research and Development of Digital Diagnosis and Treatment Equipment, 2017YFC0111404, Clinical Validation of Prostate Cancer Diagnosis by Multi-modal System, 2017-07 to 2021-12, 690,000 yuan, Conclusion, Host

近5年发表论文:

Published papers in the last 5 years:

Yang T, Chi Y, Wang X, Xu C, Chen X, Liu Y, Huang S, Zhu X, Zhang H, Zhuo H##, Wu D##. PRL-mediated STAT5B/ARRB2 pathway promotes the progression of prostate cancer through the activation of MAPK signaling. Cell Death Dis. 2024 Feb 10;15(2):128.

Yao Y, Chen X, Wang X, Li H, Zhu Y, Li X, Xiao Z, Zi T, Qin X, Zhao Y, Yang T, Wang L##, Wu G##, Fang X##, Wu D##. Glycolysis related lncRNA SNHG3 / miR-139-5p / PKM2 axis promotes castration-resistant prostate cancer (CRPC) development and enzalutamide resistance. Int J Biol Macromol. 2024 Jan 22:129635.

Zhang X, Wang Z, Huang S, He D, Yan W, Zhuang Q, Wang Z, Wang C, Tan Q, Liu Z, Yang T, Liu Y, Ren R, Li J, Butler W, Tang H, Wei GH, Li X##, Wu D##, Li Z##. Active DHEA uptake in the prostate gland correlates with aggressive prostate cancer. J Clin Invest. 2023 Dec 15;133(24):e171199.

Hong Z, Xu C, Zheng S, Wang X, Tao Y, Tan Y, Lin G, Wu D##, Ye D##. Nucleophosmin 1 cooperates with BRD4 to facilitate c-Myc transcription to promote prostate cancer progression. Cell Death Discov. 2023 Oct 24;9(1):392.

Hou Z, Huang S, Mei Z, Chen L, Guo J, Gao Y, Zhuang Q, Zhang X, Tan Q, Yang T, Liu Y, Chi Y, Qi L, Jiang T, Shao X, Wu Y, Xu X, Qin J, Ren R, Tang H##, Wu D##, Li Z##. Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer. Cell Rep Med. 2022 Mar 15;3(3):100561.

Zhao L, Han S, Su H, Li J, Zhi E, Li P, Yao C, Tian R, Chen H, Chen H, Luo J, Shi C, Ji Z, Hu J, Wu G, Zhou W, Tang Y, Chen Y, Lin G, Lue TF##, Wu D##, Li Z##. Single-cell transcriptome atlas of the human corpus cavernosum. Nat Commun. 2022 Jul 25;13(1):4302.

Hong Z, Xiang Z, Zhang P, Wu Q, Xu C, Wang X, Shi G, Hong Z, Wu D##. Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide. Clin Transl Med. 2021 Jul;11(7):e495.